Accelerating antiretroviral therapy (ART) administration, improving retention, and achieving viral suppression in low-and middle-income countries must be prioritized. We evaluated trends and disparities in these milestones in a large Latin American cohort. Adults starting ART (ART start ) from 2003 to 2014 at Caribbean, Central, and South America network for HIV epidemiology sites were assessed for care cascade outcomes: CD4 cell count >200 cells/mm 3 at ART start ; retention (!1 visit at one year after ART start ); viral suppression (!1 HIV-1 RNA <200 copies/ml at one year after ART start ). Modified Poisson regression provided adjusted prevalence ratios by age, gender, and HIV transmission risk, accounting for site and year of ART start . Proportions achieving ART start and suppression improved over time (p < 0.05). Older age was associated with better retention and viral suppression, but not ART start at CD4 cell count >200 cells/mm 3 . Females and men who have sex with men (MSM) were more likely to have CD4 cell count >200 cells/mm 3 at ART start . Injection drug users (IDUs) were less likely to be retained while MSM were more likely to achieve viral suppression (all p < 0.05). Despite improvements in these outcomes over the course of a decade in this cohort, significant disparities existed, disadvantaging younger patients, men, and IDUs. These gaps indicate continued progress in providing early diagnosis and ART start remain critical.
Background
The HIV epidemic continues to affect large and diverse populations in low-and middle-income countries, including approximately two million individuals in Latin America. 1 Within many of those countries, key populations such as men and women aged <24 years and men who have sex with men (MSM) are disproportionately affected. 2 Recent revisions to treatment guidelines in the region have emphasized improving outcomes through milestones in the care cascade: initiation of combination antiretroviral therapy (ART) closer to the time of HIV diagnosis and at higher CD4 cell counts (early ART start ), retention in HIV care, and ultimately, HIV viral suppression. 3 This is consistent with a treatment-as-prevention paradigm emphasizing ART as a pathway to improved individual-level HIV outcomes and reduced populationlevel HIV transmission. 4 Indeed, as of 2012, the number of individuals treated with ART approached 725,000 in the region, constituting fully 75% of those who were treatment eligible under the 2010 World Health Organization (WHO) guidelines. Of those receiving first-line therapy, 78% received WHOsanctioned initial regimens. 5 Despite these encouraging advances in expanding treatment, a large longitudinal analysis in high-, middle-, and low-income settings, including more than 350,000 individuals globally, demonstrated persistently lower median CD4 cell counts at ART start in low-and middle-income settings, which included Latin American countries. In particular, the proportion initiating ART at CD4 cell count <200 cells/mm 3 , representing delayed initiation, was persistently higher in these settings (59-71%, depending on gender and upper-versus lower-middle-income status), compared to high-income settings (31-35%) in 2010. 6 The high proportions with late initiation and disparities with other regions indicate an impediment to treatment-as-prevention goals for the region and merit continued monitoring of treatment uptake alongside the extension of analyses to subsequent stages of the care continuum.
Given the substantial burden of disease in the region; the need to monitor progress and temporal trends in ART initiation; the lack of other cohorts with the breadth, depth, and geographic reach of our collaboration; and the need to assess changes in the epidemiology of HIV clinical care to quantify progress and remaining gaps in clinical and public health responses, we assessed trends in these metrics over a decade in a Latin American cohort to identify key populations meriting increased attention.
Methods

Study population
Adults (!18 years) starting ART (regimen of !3 antiretroviral agents) from 2003 through 2014 at Caribbean, Central and South America network for HIV epidemiology (CCASAnet) sites were included. CCASAnet includes nine sites in seven countries, and it is one of seven member regions of the NIH-funded International Epidemiologic Databases to Evaluate AIDS. 7 
Study definitions and outcomes
The care cascade was assessed using three binary outcomes: CD4 cell count >200 cells/mm 3 at time of ART initiation (ART start ), retention in care (!1 HIV primary care visit at one year after ART start ), and viral suppression (!1 plasma HIV-1 RNA <200 copies/mL at one year after ART start ). ART start with CD4 cell count >200 cells/mm 3 was chosen to indicate the initiation of therapy before advanced disease, further indicating successful diagnosis and linkage to care at an earlier disease stage. 3 Retention and viral suppression outcomes were assessed at one year as early indicators of successful engagement in care and achievement of initial milestones in the HIV care cascade following linkage to care. 8, 9 Though individuals who died or failed to demonstrate any care engagement at all in the initial year after ART start were excluded from the retention denominator in the primary analysis, they were included in the sensitivity analysis to assess the robustness of our inferences to different inclusion criteria.
Demographic and clinical factors including age at ART start (in years), biological sex (male or female), probable HIV transmission risk factor (MSM, injection drug use [IDU], heterosexual contact [Hetero], or Other), and calendar year of ART start were included as covariates by which the probability of attaining the study outcomes may vary. Calendar year of ART start was used to assess trends in achievement of outcomes over the course of the study period. Clinic site was included as a potential confounder of these relationships.
For ART start with CD4 cell count >200 cells/mm 3 , outcomes were measured <6 months before and 7 days following ART start . ART start was an incident event, therefore each outcome anchored to this event was an incident outcome; individuals contributed a maximum of one observation for each outcome. Retention and viral suppression outcomes were assessed using the closest visit or lab measurement 90 days before/after the one-year ART start anniversary.
Individuals contributed outcomes up to 15 months following initiation of ART. Participants from GHESKIO-Haiti were excluded from viral suppression outcomes analyses due to unavailable HIV-1 RNA testing there during the study period.
Statistical analysis
Bivariate comparisons of characteristics by outcomes were conducted using Chi square and Wilcoxon rank sum tests of differences in proportions and medians for categorical and continuous variables, respectively. Modified Poisson regression was used to estimate adjusted prevalence ratios (aPR) with 95% confidence intervals (95%CI) for each outcome by age, gender, and HIV transmission risk, accounting for clinic site and calendar year of ART start ; age and year of ART start were modeled using restricted cubic splines with four knots. 10, 11 Predicted values for each outcome were predictive margins: modeled predictive values of each outcome for each patient, averaged over all patients in the study. Those with missing outcome measures or death <1 year after ART start were excluded. All analyses were conducted in Stata v.12.1 (StataCorp, College Station, TX).
Results
Among 17,653 individuals initiating ART in the CCASAnet cohort during the study period, 15,163 (85.9%) were eligible for the CD4 at ART start outcome and 17,114 (97.0%) for retention outcome analyses. Among 10,426 individuals not receiving care at GHESKIO-Haiti and initiating ART during the study period, 6159 (59.1%) were eligible for the viral suppression analysis ( Figure 1 ). (Table 2) . Upon inclusion of the 539 individuals excluded from the primary analysis in a sensitivity analysis, inferences did not change, with the sole exception of slight decreases in the relative rates of retention in care in more recent years compared to 2008: a decrease of roughly 8% in 2011 and 14% in 2013 (data not shown).
There were also significant intersite differences in each outcome, with the probability of ART start at CD4 cell count >200 cells/mm 3 ranging from 0.31 to 0.59, the probability of retention ranging from 0.65 to 0.83, and the probability of viral suppression ranging from 0.63 to 0.95 across clinical sites ( Supplementary  Figures 1 to 3, respectively) .
Though there was substantial missingness of CD4 at baseline during early years of the study (26.8% of ART initiators in 2003), adjusted probabilities of missing CD4 cell count steadily declined over time and was below 10% for nine out of 11 years in the study period ( Figure 3 ).
Discussion
In this Latin American cohort, achievement of HIV care cascade milestones generally improved over time. However, even with equivalent access to care (denoted by initiation of ART) and adjusting for site differences and secular trends, there were notable demographic and HIV transmission risk factor disparities in these care cascade outcomes.
As noted in prior work, the problems of late ART initiation persist in Latin American settings, even in the face of improved availability and uptake of ART and increasing median CD4 at ART initiation in the region. 5, 6 In Mexico, and in prior cross-sectional analyses in our entire cohort, a high prevalence of late ART initiators (76%), primarily due to late testing (diagnosis with a lower CD4 cell count), has also been described. 12, 13 This gap, despite progress, has been noted to result in adverse outcomes in both Mexico and Peru, with older individuals, those with IDU risk, and those belonging to sexual minorities at increased risk of advanced disease due to late presentation to care and ART initiation. 14, 15 In these same analyses, there was also great variation in the overall prevalence of late ART initiation between Latin American locations, and by population of interest, ranging from 49 to 91%. [12] [13] [14] [15] This observation was reflected in the differing adjusted probabilities of ART start , retention, and viral suppression outcomes across our cohort's clinical sites in this analysis.
Over the study period, there was a significant trend toward increased probabilities of initiating ART relatively 'early' (with CD4 cell count >200 cells/mm 3 ) compared to earlier years. Still, the adjusted probability of early initiation only barely exceeded 0.5 in 2014. Despite this progress toward a goal of either earlier diagnosis and initiation of therapy, or at a minimum, earlier initiation among those successfully linked to care before more advanced HIV disease progression, there obviously remains much room for improvement both in testing and linkage to care. Interestingly, the age trend observed with ART start at higher CD4 counts was counter to that observed for retention and suppression outcomes: younger age groups were more likely to start at higher CD4 counts than their middle-aged counterparts. While this cannot be confirmed without examining prelinkage data, this again suggests those with more advanced disease are less likely to be Numbers displayed as 'N(%)' except for continuous variables, which are 'Median (interquartile range)' Percentages may not sum to 100 due to rounding
Haiti excluded from viral suppression outcome due to unavailable HIV-1 RNA testing at the site during the study period.
Only odd values of 'Year of ART start' are presented, merely to save space in the linked and engaged in care at younger ages. Finally, those with Hetero transmission risk and males initiated later than MSM and females, respectively; this is consistent with other studies finding non-MSM men more likely to present to care with more advanced disease (i.e. lower CD4 counts). 16, 17 In assessing retention immediately following ART start , IDU as HIV transmission risk was associated with the largest significant reduction in retention. The effect size was large (28% reduced probability of retention versus those with Hetero risk) and the unadjusted proportion of those not retained at one year was more than 45%. Though the association was observed in analyses that adjusted for other demographic and clinical characteristics, the influence of unmeasured factors such as psychiatric and mental health comorbidities, structural barriers to care (e.g. criminalization and stigma), and socioeconomic and geographic factors linked to healthcare access (such as income and lack of transportation networks) may be substantial. The IDU risk group was also a small population (<1%) within this cohort, reflecting earlier United Nations estimates of a 0.33% point prevalence of IDU in the general population aged 15-64 in Latin America and the Caribbean. 18 Despite lower prevalence of IDU in Latin America than in Europe (1.26%) or North America (0.66%), these analyses reflect similar inferences as those drawn from related care cascade analyses in our cohort, calling attention to the need to address retention in this risk group and offer targeted responses to the specific needs of this population. 19, 20 Younger age also emerged as a significant predictor of poorer retention and viral suppression outcomes, similar to studies in other settings, though the magnitude of these effects was not large. 21, 22 This disparity may be related to differences in ongoing healthcare access, risk behaviors, or perhaps active substance use which may be more prevalent in younger populations and which was unaccounted for in these analyses. [23] [24] [25] The need for interventions to address substance use and improve screening, particularly in prenatal settings and during prediagnosis engagement in medical care for symptoms, remains a priority. 14, 15 This study had several limitations. First, these results may not be generalizable to persons living with HIV not successfully linked to care, as this population was already engaged in care. More vulnerable populations or those who progressed to death without receiving care may have been excluded, introducing possible bias. Second, there were missing CD4 counts at baseline, affecting the estimation of the ART start at CD4 cell count >200 cells/mm 3 outcome, though this was more pronounced earlier in the study than later (e.g. 27% missing in 2003 versus 9% in 2012); multiple imputation was not used for outcome missingness due to identical covariates available for imputation being used in the final model for the outcome. Finally, these data are serial cross-sections, and it may be possible that individuals followed for longer periods would have exhibited different retention or viral suppression likelihoods as they experienced greater exposure to the healthcare system; however, assessments of retention and viral suppression immediately following ART start have been shown to be important prognostic markers of future outcomes, with worse retention typically occurring within the first year of treatment. 26 Despite these limitations, this remains a valuable evaluation of critical cascade of care outcomes in lower-and middle-income settings in the Western Hemisphere. These findings provide a basis for cautious optimism that, despite persisting disparities affecting younger, male, and IDU populations, there are general improvements in the important cascade milestones of earlier ART start , retention on ART, and viral suppression immediately following ART start in Latin America. Once ART is started, focused efforts must be made to keep younger patients and those with IDU history engaged in care, to improve goals of sustained viral suppression and attendant survival and transmission benefits. 
